Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303
Stifel analyst Shlomo Rosenbaum maintains IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $276 to $303.
Stocks · News reference
IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studies
IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on IQVIA Holdings, Raises Price Target to $300
Mizuho analyst Ann Hynes maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $275 to $300.
Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $300
Barclays analyst Luke Sergott maintains IQVIA Holdings (NYSE:IQV) with a Overweight and raises the price target from $275 to $300.
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
iOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization. The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.
Veeva Systems shares are trading higher after the company announced an expansion of its partnership with IQVIA with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies.
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
Veeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates.